MedCity News July 17, 2020
A Q&A with executives from Seven Bridges, a bioinformatics analysis business, highlights the company’s work in the precision medicine sector.
An interview with William (Bill) Moss, CEO, and Brandi Davis-Dusenbery, CSO, of bioinformatics business Seven Bridges.
Why did you join this company?
Bill: The majority of my career has focused on identifying transformative technologies and companies that I believe will have significant societal impact. I joined Seven Bridges with the belief that this company has the right people, technology and resources to lead a bioinformatics revolution that will accelerate scientific discovery and development of novel precision medicines and therapies for patients. Through our work we are creating valuable precision medicine solutions for an ever-increasing number of highly targeted patient populations,...
Today's Sponsors
Today's Sponsor